Description
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group.
Tesamorelin (also known as Egrifta) is a synthetic form which is used in the treatment of HIV-associated lipodystrophy.
Tesamorelin has been shown to reduce lipodystrophy in HIV-infected individuals. Lipodystrophy is a condition that causes changes in placement of body fat, including wasting and fat accumulation, and changes in metabolism.
which may be taken with GHRP-6 is clinical trials, that also promotes production and possible fat loss. Individuals with lipodystrophy may develop excess fat most notably around the liver, stomach, and other abdominal organs (visceral body fat).
